Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide

Infection and Immunity

Volumn 72, Issue 6, 2004, Pages 3344-3349

  Sprong, Tom ^a   Møller, Anne Sophie W ^b   Bjerre, Anna ^b   Wedege, Elisabeth ^c   Kierulf, Peter ^b   Van Der Meer, Jos W M ^a   Brandtzaeg, Petter ^b   Van Deuren, Marcel ^a   Mollnes, T E ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CD11B ANTIGEN; CD18 ANTIGEN; CHEMOKINE; COMPLEMENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEPIRUDIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL STRAIN; COMPLEMENT ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAM NEGATIVE SEPSIS; GRANULOCYTE; HUMAN; HUMAN CELL; INFLAMMATION; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY BURST; UPREGULATION; WILD TYPE;

EID: 2542517038     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.6.3344-3349.2004     Document Type: Article

References (44)

1. Bjerre, A., B. Brusletto, T. E. Mollnes, E. Fritzsonn, E. Rosenqvist, E. Wedege, E. Namork, P. Kierulf, and P. Brandtzaeg. 2002. Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria and an LPS-free mutant. J. Infect. Dis. 15:220-228.
2. Bjerre, A., B. Brusletto, E. Rosenquist, E. Namork, P. Kierulf, R. Ovstebo, G. B. Joo, and P. Brandtzaeg. 2000. Cellular activating properties and morphology of membrane-bound and purified meningococcal lipopolysaccharide. J. Endotoxin Res. 6:437-445.
3. Brandtzaeg, P., A. Bjerre, R. Ovstebo, B. Brusletto, G. B. Joo, and P. Kierulf. 2001. Neisseria meningitidis lipopolysaccharides in human pathology. J. Endotoxin Res. 7:401-420.
4. Brandtzaeg, P., T. E. Mollnes, and P. Kierulf. 1989. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 160:58-65.
5. Brandtzaeg, P., R. Ovstebo, and P. Kierulf. 2000. Quantitative detection of bacterial lipopolysaccharides in clinical specimens, p. 427-439. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal disease. Humana Press, Totowa, N.Y.
6. Brandtzaeg, P., and M. van Deuren. 2002. Current concepts in the role of the host response in Neisseria meningitidis septic shock. Curr. Opin. Infect. Dis. 15:247-252.
7. Cavaillon, J. M., C. Fitting, and N. Haeffner-Cavaillon. 1990. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur. J. Immunol. 20:253-257.
8. Chateau, M. T., and R. Caravano. 1997. The oxidative burst triggered by Salmonella typhimurium in differentiated U937 cells requires complement and a complete bacterial lipopolysaccharide. FEMS Immunol. Med. Microbiol. 17:57-66.
9. Dahinden, C., C. Galanos, and J. Fehr. 1983. Granulocyte activation by endotoxin. I. Correlation between adherence and other granulocyte functions, and role of endotoxin structure on biologic activity. J. Immunol. 130:857-862.
10. Estabrook, M. M., D. L. Jack, N. J. Klein, and G. A. Jarvis. 2004. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J. Immunol. 172:3784-3792.
11. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
12. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, and U. Rye. 1991. Production, characterization, and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-79.
13. Fure, H., E. W. Nielsen, C. E. Hack, and T. E. Mollnes. 1997. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 46:553-557.
14. Hackett, S. J., M. Guiver, J. Marsh, J. A. Sills, A. P. J. Thomson, E. B. Kaczmarski, and C. A. Hart. 2002. Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch. Dis. Child. 86:44-46.
15. Halstensen, A., M. Ceska, P. Brandtzaeg, H. Redl, A. Naess, and A. Waage. 1993. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J. Infect. Dis. 167:471-475.
16. Hangen, D. H., J. H. Stevens, P. S. Satoh, E. W. Hall, P. T. O'Hanley, and T. A. Raffin. 1989. Complement levels in septic primates treated with anti-C5a antibodies. J. Surg. Res. 46:195-199.
17. Hazelzet, J. A., R. de Groot, G. van Mierlo, K. F. M. Joosten, E. van der Voort, A. Eerenberg, M. H. Suur, W. C. J. Hop, and C. E. Hack. 1998. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect. Immun. 66:5350-5356.
18. Hibberd, M. L., M. Sumiya, J. A. Summerfield, R. Booy, M. Levin, and the Meningococcal Research Group. 1999. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 353:1049-1053.
19. Holten, E. 1979. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 9:186-188.
20. Hughes, J. E., J. Stewart, G. R. Barclay, and J. R. W. Govan. 1997. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect. Immun. 65:4281-4287.
21. Kurt-Jones, E. A., L. Mandell, C. Whitney, A. Padgett, K. Gosselin, P. E. Newburger, and R. W. Finberg. 2002. Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood 100:1860-1868.
22. Mirlashari, M. R., E. A. Hoihy, J. Holst, and T. Lyberg. 2002. Outer membrane vesicles from Neisseria meningitidis. APMIS 110:193-204.
23. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100:1869-1877.
24. Mollnes, T. E., T. Lea, S. S. Froland, and M. Harboe. 1985. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22:197-202.
25. Mollnes, T. E., W. C. Song, and J. D. Lambris. 2002. Complement in inflammatory tissue damage and disease. Trends Immunol. 23:61-64.
26. Morrison, D. C., and L. F. Kline. 1977. Activation of the classical and properdin pathways of complement activation by bacterial lipopolysaccharides (LPS). J. Immunol. 118:362-368.
27. Okusawa, S., K. B. Yancey, J. W. van der Meer, S. Endres, G. Lonnemann, K. Hefter, M. M. Frank, J. F. Burke, C. A. Dinarello, and J. A. Gelfand. 1988. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J. Exp. Med. 168:443-448.
28. Pridmore, A. C., D. H. Wyllie, F. Abdillahi, L. Steeghs, P. van der Ley, S. K. Dower, and R. C. Read. 2001. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signal via Toll-like receptor (TLR) 2, but not via TLR4/MD2. J. Infect. Dis. 183:89-96.
29. Ross, S. C., and P. Densen. 1984. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63:243-273.
30. Sprong, T., P. Brandtzaeg, M. Fung, A. M. Pharo, E. A. Hoiby, T. E. Michaelsen, A. Aase, J. W. van der Meer, M. van Deuren, and T. E. Mollnes. 2003. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102:3702-3710.
31. Sprong, T., N. Stikkelbroeck, P. van der Ley, L. Steeghs, L. van Alphen, N. Klein, M. G. Netea, J. W. M. van der Meer, and M. van Deuren. 2001. Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J. Leukoc. Biol. 70:283-288.
32. Steeghs, L., H. de Cock, E. Evers, B. Zomer, J. Tommassen, and P. van der Ley. 2001. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J. 20:6927-6945.
33. Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der Ley. 1998. Meningitis bacterium is viable without endotoxin. Nature 392:449-450.
34. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
35. Uronen, H., A. J. Williams, G. Dixon, S. R. Andersen, P. Van der Ley, M. Van Deuren, R. E. Callard, and N. Klein. 2000. Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS). Clin. Exp. Immunol. 22:312.
36. Van Deuren, M., P. Brandtzaeg, and J. W. M. Van der Meer. 2000. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev. 13:144-166.
37. Van Deuren, M., J. van der Ven-Jongekrijg, E. Vannier, R. van Dalen, G. Pesman, A. K. M. Bartelink, C. A. Dinarello, and J. W. M. van der Meer. 1997. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 90:1101-1108.
38. a. Van Deventer, S. J., H. R. Buller, J. W. ten Cate, L. A. Aarden, C. E. Hack, and A. Sturk. 1990. Experimental endotixaemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520-2526.
39. van Leenen, D., T. van der Poll, M. Levi, H. Ten Cate, S. J. van Deventer, C. E. Hack, L. A. Aarden, and J. W. Ten Cate. 1993. Pentoxifylline attenuates neutrophil activation in experimental endotoxaemia in chimpanzees. J. Immunol. 151:2318-2325.
40. Vukajlovich, S. W., J. Hoffman, and D. C. Morrison. 1987. activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathways. Mol. Immunol. 24:319-331.
41. Waage, A., A. Halstensen, and T. Espevik. 1987. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet i:355-357.
42. Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Froholm. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcus class 1 proteins. J. Med. Microbiol. 38:23-28.
43. Westphal, O., and J. K. Jann. 1965. Bacterial lipopolysaccharide extraction with phenol-water and further application of the procedure. Methods Carbohydr. Chem. 5:83-91.
44. Wolbink, G. J., J. Bollen, J. W. Baars, R. J. M. Tenberge, A. J. G. Swaak, J. Paardekooper, and C. E. Hack. 1993. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 163:67-76.